Journal watch provides very useful information
Featured in NEJM Journal Watch: Spironolactone Mitigates Rosacea Risk — Physician’s First Watch
Featured in NEJM Journal Watch: Spironolactone Mitigates Rosacea Risk
By the NEJM Journal Watch Editors
In a large population-based analysis, spironolactone users had lower-than-expected rates of incident rosacea.
Mark Dahl, a dermatologist for NEJM Journal Watch, reminds readers: "Spironolactone is not FDA approved to treat rosacea. This study assesses the risk for developing rosacea; it does not assess the ability of oral spironolactone to treat rosacea of any subtype."